Exicure Research and Development Expenses 2017-2025 | XCUR

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Exicure research and development expenses from 2017 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.

Exicure Research and Development Expenses 2017-2025 | XCUR

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Exicure research and development expenses from 2017 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$218.1B
Amgen (AMGN)	$157.3B
Gilead Sciences (GILD)	$135.7B
Vertex Pharmaceuticals (VRTX)	$119.2B
Bristol Myers Squibb (BMY)	$94.5B
CSL (CSLLY)	$78.8B
GSK (GSK)	$77.4B
Regeneron Pharmaceuticals (REGN)	$59.2B
Alnylam Pharmaceuticals (ALNY)	$40.6B
Argenex SE (ARGX)	$34B
BioNTech SE (BNTX)	$26.6B
Royalty Pharma (RPRX)	$20.5B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$15.4B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.6B
Incyte (INCY)	$13.2B
Moderna (MRNA)	$12.2B
Exelixis (EXEL)	$12B
BioMarin Pharmaceutical (BMRN)	$10.9B
Ascendis Pharma (ASND)	$10.7B
QIAGEN (QGEN)	$10.5B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$10B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.4B
Bio-Techne Corp (TECH)	$8.1B
Roivant Sciences (ROIV)	$7.7B
Legend Biotech (LEGN)	$7.3B